The expression and prognostic predictive value of PD-L2 in patients undergoing radical gastric cancer surgery.

IF 2.1 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-07-02 DOI:10.1080/20565623.2025.2526993

Xiuping Zhang, Maodong Fu, Zhiyong Li, Feng Shen, Huan Chen, Zhiming Wang, Jingmei Zheng

{"title":"The expression and prognostic predictive value of PD-L2 in patients undergoing radical gastric cancer surgery.","authors":"Xiuping Zhang, Maodong Fu, Zhiyong Li, Feng Shen, Huan Chen, Zhiming Wang, Jingmei Zheng","doi":"10.1080/20565623.2025.2526993","DOIUrl":null,"url":null,"abstract":"Background: The expression and prognostic predictive value of programmed death-ligand 2 (PD-L2) in patients undergoing radical gastric cancer (GC) surgery remains unclear.Methods: PD-L2 expression in tumor cells (TC) and tumor-infiltrating immune cells (TIIC) was evaluated by immunohistochemistry. Kaplan-Meier and Cox models were used to evaluate the association of PD-L2 with disease-free survival (DFS) and overall survival (OS).Results: This study included 299 patients and the average age was 63.76 ± 11.83 years, with 218 males (72.91%) and 81 females (27.09%). TC PD-L2 expression was significantly associated with poorer DFS (HR = 2.177, 95% CI 1.364-3.474, P = 0.001) and OS (HR = 1.943, 95% CI 1.191-3.169, P = 0.008). Multivariate analysis confirmed TC PD-L2 expression as an independent poor prognostic factor for DFS (HR = 2.121, 95% CI 1.325-3.393, P = 0.002) and OS (HR = 1.812, 95% CI 1.109-2.961, P = 0.018). PD-L2 in TIIC did not correlate with survival. Other poor prognostic factors included age ≥60, vascular invasion, advanced postoperative stage, and HER2 positivity.Conclusions: PD-L2 expression in TC is an independent prognostic biomarker in GC, linked to poorer DFS and OS, suggesting its potential for identifying high-risk patients for personalized therapies.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2526993"},"PeriodicalIF":2.1000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233815/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Science OA","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20565623.2025.2526993","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/2 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The expression and prognostic predictive value of programmed death-ligand 2 (PD-L2) in patients undergoing radical gastric cancer (GC) surgery remains unclear.

Methods: PD-L2 expression in tumor cells (TC) and tumor-infiltrating immune cells (TIIC) was evaluated by immunohistochemistry. Kaplan-Meier and Cox models were used to evaluate the association of PD-L2 with disease-free survival (DFS) and overall survival (OS).

Results: This study included 299 patients and the average age was 63.76 ± 11.83 years, with 218 males (72.91%) and 81 females (27.09%). TC PD-L2 expression was significantly associated with poorer DFS (HR = 2.177, 95% CI 1.364-3.474, P = 0.001) and OS (HR = 1.943, 95% CI 1.191-3.169, P = 0.008). Multivariate analysis confirmed TC PD-L2 expression as an independent poor prognostic factor for DFS (HR = 2.121, 95% CI 1.325-3.393, P = 0.002) and OS (HR = 1.812, 95% CI 1.109-2.961, P = 0.018). PD-L2 in TIIC did not correlate with survival. Other poor prognostic factors included age ≥60, vascular invasion, advanced postoperative stage, and HER2 positivity.

Conclusions: PD-L2 expression in TC is an independent prognostic biomarker in GC, linked to poorer DFS and OS, suggesting its potential for identifying high-risk patients for personalized therapies.

Abstract Image

查看原文本刊更多论文

PD-L2在胃癌根治性手术患者中的表达及预后预测价值

背景：程序性死亡配体2 （PD-L2）在根治性胃癌（GC）手术患者中的表达及其预后预测价值尚不清楚。方法：采用免疫组化方法检测PD-L2在肿瘤细胞（TC）和肿瘤浸润免疫细胞（TIIC）中的表达。采用Kaplan-Meier和Cox模型评估PD-L2与无病生存期（DFS）和总生存期（OS）的关系。结果：纳入299例患者，平均年龄63.76±11.83岁，其中男性218例（72.91%），女性81例（27.09%）。TC PD-L2表达与较差的DFS （HR = 2.177, 95% CI 1.364 ~ 3.474, P = 0.001）和OS （HR = 1.943, 95% CI 1.191 ~ 3.169, P = 0.008）显著相关。多因素分析证实TC PD-L2表达是DFS （HR = 2.121, 95% CI 1.325 ~ 3.393, P = 0.002）和OS （HR = 1.812, 95% CI 1.109 ~ 2.961, P = 0.018）的独立预后不良因素。TIIC患者的PD-L2与生存率无相关性。其他不良预后因素包括年龄≥60岁、血管侵犯、术后晚期和HER2阳性。结论：PD-L2在TC中的表达是GC中独立的预后生物标志物，与较差的DFS和OS相关，提示其具有识别高危患者进行个性化治疗的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Science OA MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

5.00

自引率

4.00%

发文量

审稿时长

13 weeks

期刊介绍： Future Science OA is an online, open access, peer-reviewed title from the Future Science Group. The journal covers research and discussion related to advances in biotechnology, medicine and health. The journal embraces the importance of publishing all good-quality research with the potential to further the progress of research in these fields. All original research articles will be considered that are within the journal''s scope, and have been conducted with scientific rigour and research integrity. The journal also features review articles, editorials and perspectives, providing readers with a leading source of commentary and analysis. Submissions of the following article types will be considered: -Research articles -Preliminary communications -Short communications -Methodologies -Trial design articles -Trial results (including early-phase and negative studies) -Reviews -Perspectives -Commentaries